- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis
- Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion
PR Newswire
SAN DIEGO, May 8, 2019